• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC.

作者信息

Jørgensen Jan Trøst

机构信息

Medical Sciences, Dx-Rx Institute, Fredensborg, Denmark.

出版信息

Chin Clin Oncol. 2020 Aug;9(4):60. doi: 10.21037/cco.2020.01.03. Epub 2020 Feb 11.

DOI:10.21037/cco.2020.01.03
PMID:32075393
Abstract
摘要

相似文献

1
PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC.PD-L1表达与帕博利珠单抗单药治疗非小细胞肺癌的疗效
Chin Clin Oncol. 2020 Aug;9(4):60. doi: 10.21037/cco.2020.01.03. Epub 2020 Feb 11.
2
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.一线帕博利珠单抗单药治疗高龄（≥75 岁）非小细胞肺癌患者的疗效和安全性。
J Cancer Res Clin Oncol. 2020 Feb;146(2):457-466. doi: 10.1007/s00432-019-03072-1. Epub 2019 Dec 18.
3
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
4
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.帕博利珠单抗作为程序性死亡受体配体1（PD-L1）阳性晚期非小细胞肺癌患者的一线治疗：一项1期试验。
Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.
5
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.帕博利珠单抗联合化疗对比化疗联合帕博利珠单抗单药一线治疗美国鳞状非小细胞肺癌的成本效果分析。
Curr Med Res Opin. 2019 Jul;35(7):1241-1256. doi: 10.1080/03007995.2019.1571297. Epub 2019 Jan 29.
6
Pembrolizumab for all PD-L1-positive NSCLC.帕博利珠单抗用于所有PD-L1阳性非小细胞肺癌。
Lancet. 2019 May 4;393(10183):1776-1778. doi: 10.1016/S0140-6736(18)32559-5. Epub 2019 Apr 4.
7
First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment.一线帕博利珠单抗单药治疗转移性PD-L1阳性非小细胞肺癌：治疗时间的真实世界分析
Immunotherapy. 2019 Jul;11(10):889-901. doi: 10.2217/imt-2019-0061. Epub 2019 Jun 11.
8
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.帕博利珠单抗作为一线治疗药物治疗程序性死亡配体-1 超高表达的非小细胞肺癌患者的临床结局：日本多中心回顾性队列研究。
PLoS One. 2019 Jul 31;14(7):e0220570. doi: 10.1371/journal.pone.0220570. eCollection 2019.
9
Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.经治非小细胞肺癌患者中PD-1/PD-L1抑制剂（纳武利尤单抗、帕博利珠单抗和阿特珠单抗）的比较：来自贝叶斯网络模型的证据
Int J Cancer. 2018 Dec 1;143(11):3038-3040. doi: 10.1002/ijc.31733. Epub 2018 Sep 25.
10
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.帕博利珠单抗对比标准治疗化疗用于 PD-L1 阳性（>50%）转移性鳞状和非鳞状非小细胞肺癌一线治疗的成本效果分析。在法国。
Lung Cancer. 2019 Jan;127:44-52. doi: 10.1016/j.lungcan.2018.11.008. Epub 2018 Nov 23.

引用本文的文献

1
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.AK112，一种新型的PD-1/血管内皮生长因子双特异性抗体，联合化疗用于晚期非小细胞肺癌（NSCLC）患者：一项开放标签、多中心、II期试验。
EClinicalMedicine. 2023 Aug 3;62:102106. doi: 10.1016/j.eclinm.2023.102106. eCollection 2023 Aug.
2
Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance.免疫检查点抑制剂与放射治疗联合用于癌症治疗：打破耐药壁垒的重锤。
Front Oncol. 2022 Dec 5;12:1035884. doi: 10.3389/fonc.2022.1035884. eCollection 2022.
3
Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise.
免疫检查点抑制剂的癌症免疫治疗——反应和毒性的生物标志物；当前局限性与未来前景
Diagnostics (Basel). 2022 Jan 6;12(1):124. doi: 10.3390/diagnostics12010124.
4
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.非小细胞肺癌的一线免疫检查点抑制剂：现状与未来进展
Front Pharmacol. 2020 Oct 7;11:578091. doi: 10.3389/fphar.2020.578091. eCollection 2020.